Search Result

Results for "

cxcr

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CXCR (259) Adrenergic Receptor (2) Akt (5) Apelin Receptor (APJ) (3) Apoptosis (14) Arrestin (6) Autophagy (1) Biochemical Assay Reagents (2) Cadherin (1) Calcium Channel (2) Caspase (2) CCR (9) CX3CR1 (1) Dengue Virus (2) Drug Metabolite (3) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (9) ERK (4) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) Fungal (2) GPR35 (8) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (6) HIV (33) HSV (1) IFNAR (1) iGluR (5) Interleukin Related (6) Isotope-Labeled Compounds (6) JNK (1) Microtubule/Tubulin (2) MOFs (1) mRNA (6) NOD-like Receptor (NLR) (1) NTPDase (1) Opioid Receptor (1) Oxidative Phosphorylation (2) P2X Receptor (1) p38 MAPK (2) Protein Arginine Deiminase (1) Radionuclide-Drug Conjugates (RDCs) (5) Reactive Oxygen Species (ROS) (1) Reference Standards (21) Small Interfering RNA (siRNA) (18) STAT (1) TNF Receptor (1) VEGFR (1) Virus Protease (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (122) Cardiovascular Disease (7) Endocrinology (69) Infection (46) Inflammation/Immunology (134) Metabolic Disease (7) Neurological Disease (18)
Oligonucleotides:	Chemokine & Receptors (6) Rat Pre-designed siRNA Sets (6) mRNA (6) Mouse Pre-designed siRNA Sets (6) Human Pre-designed siRNA Sets (6) siRNAs (18)

279

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: CXCR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15251

Reparixin 60+ Cited Publications Repertaxin; DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-10198

Navarixin 30+ Cited Publications SCH 527123; MK-7123	CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both *CXCR1* and *CXCR2, with K_d* values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly .

HY-122197

ML339 4 Publications Verification	CXCR Apelin Receptor (APJ) Arrestin	Cancer
ML339 is a selective *CXCR6* antagonist with an IC₅₀ of 140 nM. ML339 antagonizes β-arrestin recruitment and cAMP signaling pathway of human CXCR6 receptor induced by CXCL16, with IC₅₀ of 0.3 μM and 1.4 μM, respectively. ML339 shows weaker activity against the recruitment of β-arrestin in mouse *CXCR6* receptors, with an IC₅₀ of 18 μM. ML339 has no inhibitory effect on *CXCR5，CXCR4，CXCR6* and apelin receptor (APJ), with IC₅₀ >79 μM. ML339 has the potential to promote the development of prostate cancer research .

HY-12488

LY2510924 Maximum Cited Publications 13 Publications Verification	CXCR	Endocrinology Cancer
LY2510924 is a potent and selective *CXCR4* antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-15252

Reparixin L-lysine salt 60+ Cited Publications Repertaxin L-lysine salt	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

HY-101458A

IT1t dihydrochloride 5 Publications Verification	CXCR HIV	Inflammation/Immunology Endocrinology Cancer
IT1t dihydrochloride is a potent *CXCR4* antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-139643

CXCR7 antagonist-1 2 Publications Verification	CXCR Adrenergic Receptor	Inflammation/Immunology Cancer
CXCR7 antagonist-1 is a *CXCR7* antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases .

HY-P990254

*Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)*	CXCR	Inflammation/Immunology Cancer
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse *CXCR3/CD183* IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 ⁺ and CD8 ⁺ T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable *CXCR2* antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM .

HY-101022

CXCR2-IN-1 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
CXCR2-IN-1 is a central nervous system penetrant *CXCR2* antagonist with a pIC₅₀ of 9.3.

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human cxcr4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective *CXCR4* antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-13696

MSX-122 1 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
MSX-122 is an orally active partial antagonist of *CXCR4, inhibiting CXCR4/CXCL12* actions, with an IC₅₀ of ∼10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.

HY-167851

CCX662	CXCR	Neurological Disease Cancer
CCX662 is a selective *CXCR7* inhibitor with human IC₅₀ values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC₅₀ of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7, inhibits *CXCR4*-directed trans-endothelial migration of *CXCR4* ⁺/CXCR7 ⁺ cells. CCX662 can be used for the research of glioblastoma multiforme .

HY-139643A

CXCR7 antagonist-1 hydrochloride 2 Publications Verification	CXCR Adrenergic Receptor	Inflammation/Immunology Cancer
CXCR7 antagonist-1 hydrochloride is a *CXCR7* antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases .

HY-112154

CXCR7 modulator 2	CXCR	Cardiovascular Disease Endocrinology
CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a K_i of 13 nM.

HY-100677

VUF11207 3 Publications Verification	CXCR	Endocrinology
VUF11207 (Compound 29) is a *CXCR7* agonist and a high-potency *CXCR7* (pK_i of 8.1) ligand that induces recruitment of β-arrestin2 (pEC₅₀ of 8.8) and subsequent internalization (pEC₅₀ of 7.9) of *CXCR7* .

HY-161735

CXCR4-IN-3	CXCR	Inflammation/Immunology
CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor *CXCR4, with an IC₅₀* of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .

HY-147392

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective *CXCR2* antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

HY-107987

CXCR7 modulator 1	CXCR	Endocrinology
CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid *CXCR7* modulator, with a K_i of 9 nM .

HY-128063

CXCR3 antagonist 1	CXCR	Inflammation/Immunology
CXCR3 antagonist 1 (compound 6c) is a selective and non-cytotoxic *CXCR3* antagonist (IC₅₀=0.06 µM). CXCR3 antagonist 1 has potential in researching inflammatory diseases (including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes) .

HY-RS03403

CXCR3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR3 Human Pre-designed siRNA Set A CXCR3 Human Pre-designed siRNA Set A

HY-163480

PF-06835375	CXCR	Inflammation/Immunology
PF-06835375 is a selective, humanized *CXCR5*-targeting immunoglobulin G1 antibody. PF-06835375 depletes *CXCR5*-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases .

HY-146401

CXCR4 antagonist 6	CXCR	Cancer
CXCR4 antagonist 6 (compound 46) is a potent *CXCR4* antagonist with an IC₅₀ value of 79 nM. CXCR4 antagonist 6 inhibits CXCL12 induced cytosolic calcium flux (IC₅₀ = 0.25 nM). CXCR4 antagonist 6 significantly mitigates CXCL12/CXCR4 mediated cell migration. CXCR4 antagonist 6 exhibits marked efficacy in a cancer metastasis model in mice .

HY-163475

*CXCL-CXCR1/2-IN-1* 1 Publications Verification	CXCR	Cancer
CXCL-CXCR1/2-IN-1 is an orally active ELR ⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2 . CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects .

HY-139873

CXCR2 antagonist 2	CXCR	Cancer
CXCR2 antagonist 2 is a potent *CXCR2* antagonist for cancer immunoresearch with an IC₅₀ value of 95 nM.

HY-P990394

*Anti-CXCR3/GPR9/CD183 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting *CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR*3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-101458

IT1t	CXCR HIV	Inflammation/Immunology Endocrinology
IT1t is a potent *CXCR4* antagonist; inhibits CXCL12/CXCR4 interaction with an IC₅₀ of 2.1 nM.

HY-179387

CXCR2-IN-3	CXCR Autophagy NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) Apoptosis	Cancer
CXCR2-IN-3 is a *CXCR2* inhibitor with an IC₅₀ of 11.37 μM. CXCR2-IN-3 mediates CXCR2-Ca ²⁺ signalling inhibition halted autophagic flux, subsequently facilitating ROS-mediated apoptotic cell death. CXCR2-IN-3 suppresses the CXCR2-NLRP3 canonical pathway, suppressing pre-tumorigenic markers. CXCR2-IN-3 causes autophagy-dependent cell death in polyploid giant cancer cells (PGCCs). CXCR2-IN-3 can be used for the research of oral squamous cell carcinoma (OSCC) .

HY-174728

*Human CXCR1 mRNA*	mRNA	Inflammation/Immunology
Human CXCR1 mRNA encodes the human C-X-C motif chemokine receptor 1 (CXCR1) protein, a member of the G-protein-coupled receptor family. CXCR1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system.

HY-P5297

*DOTA-CXCR4-L*	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a *CXCR4* targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR2 Human Pre-designed siRNA Set A CXCR2 Human Pre-designed siRNA Set A

HY-RS03406

CXCR4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR4 Human Pre-designed siRNA Set A CXCR4 Human Pre-designed siRNA Set A

HY-136437

CXCR4 antagonist 1	CXCR HIV	Infection
CXCR4 antagonist 1 is a potent *CXCR4* antagonist. CXCR4 antagonist 1 has anti-HIV activity .

HY-144286

CXCR4 antagonist 3	CXCR	Infection
CXCR4 antagonist 3 (compound 12a) is a potent antagonist of *CXCR4* with an IC₅₀ of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus .

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-139874

CXCR2 antagonist 3	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3 ⁺ T lymphocytes into the Pan02 tumor tissues .

HY-147979

CXCR4 antagonist 9	CXCR	Infection Cancer
CXCR4 antagonist 9 (Compound 2) is a *CXCR4* antagonist with an IC₅₀ of 15 nM. CXCR4 antagonist 9 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 1.3 nM .

HY-P991227

*Anti-CD185/CXCR5 Antibody* BAY-924 antibody	CXCR	Cancer
Anti-CD185/CXCR5 Antibody is an antibody inhibitor, targeting to human CD185/CXCR5.

HY-120878A

*(R,R)-CXCR2-IN-2*	CXCR	Neurological Disease Inflammation/Immunology Cancer
(R,R)-CXCR2-IN-2 (compound 67), diastereoisomer of CXCR2-IN-2 (compound 68) (HY-120878), is a *CXCR2* antagonist with a pIC₅₀ of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively .

HY-147808

CXCR4 antagonist 7	CXCR HIV	Infection Inflammation/Immunology Cancer
CXCR4 antagonist 7 (Compound PARA-B) is a *CXCR4* antagonist with the IC₅₀ of 9.3 nM. CXCR4 antagonist 7 can be used for the research of HIV infection, inflammatory diseases, cancer, and WHIM syndrome .

HY-P990395

*Anti-CXCR4/CD184 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets *CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR*4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-P11011

Peptide R54 Pep R54; cxcr4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting *CXCR4* with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective *CXCR4* antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4810

Polyphemusin II-Derived Peptide T140	CXCR	Infection
Polyphemusin II-Derived Peptide (T140), a *CXCR4* inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .

HY-153464

CXCR4-IN-1	CXCR	Infection Cardiovascular Disease Inflammation/Immunology Cancer
CXCR4-IN-1 (Example C5) is a *CXCR4* inhibitor (IC₅₀: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc .

HY-149558

CXCR4-IN-2	Apoptosis CXCR	Cancer
CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule that is a potent CXCR4 inhibitor with anticancer activity. CXCR4-IN-2 has cytotoxic (IC₅₀: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. CXCR4-IN-2 induces cell arrest in the G2/M phase and induces apoptosis .

HY-147978

CXCR4 antagonist 8	CXCR	Infection Cancer
CXCR4 antagonist 8 (Compound 3) is a *CXCR4* antagonist with an IC₅₀ of 57 nM. CXCR4 antagonist 8 inhibits CXCL12 induced cytosolic calcium increase with an IC₅₀ of 0.24 nM. CXCR4 antagonist 8 inhibits CXLC12/CXCR4 mediated cell migration .

HY-146053

CXCR4 modulator-1	CXCR	Infection Inflammation/Immunology Cancer
CXCR4 modulator-1 (compound ZINC72372983) is a potent *CXCR4* modulator with an EC₅₀ value of 100 nM. CXCR4 modulator-1 can be used for researching anti-inflammatory, anticancer and anti-HIV .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

783 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 783 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Target	Research Area

HY-12488

LY2510924 Maximum Cited Publications 13 Publications Verification	CXCR	Endocrinology Cancer
LY2510924 is a potent and selective *CXCR4* antagonist that blocks SDF-1 binding to CXCR4 with an IC₅₀ of 0.079 nM.

HY-P0171

Motixafortide 3 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel *CXCR4* antagonist with an IC₅₀ vakue of ～1 nM.

HY-P0172

ATI-2341 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 *(CXCR4)*, which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective *CXCR4* antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P1102

TC14012 4 Publications Verification	CXCR HIV	Infection Cancer
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets *CXCR4*. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3612

CTCE-0214	CXCR	Inflammation/Immunology
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .

HY-P0172A

ATI-2341 TFA 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P2218

Anditixafortide	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1104A

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a *CXCR4* antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

HY-P1682

Balixafortide 1 Publications Verification POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic *CXCR4* antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for *CXCR4* than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P4111

Peptide R	CXCR	Inflammation/Immunology Cancer
Peptide R is a cyclic peptide and a specific *CXCR4* antagonist. Peptide R exhibits excellent ability to effectively remodel tumor stroma. Peptide R has potential for use in tumor research .

HY-P4846

Ac-Pro-Gly-Pro-OH 2 Publications Verification	CXCR Apoptosis IFNAR TNF Receptor Interleukin Related	Infection Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a *CXCR2* agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer .

HY-P10427

DV1	CXCR Dengue Virus	Neurological Disease Inflammation/Immunology Cancer
DV1 is a *CXCR4* inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases .

HY-P10415

EPI-X4 1 Publications Verification hSA(408–423) peptide	CXCR	Infection Inflammation/Immunology Cancer
EPI-X4 (hSA408–423 peptide) is an antagonist for C-X-C motif chemokine receptor 4 (CXCR4) with IC₅₀ of 8.6 μM. EPI-X4 blocks the CXCL12-mediated signaling, inhibits chemokine-mediated migration and invasion of leukemia cell. EPI-X4 exhibits anti-inflammatory activity in mouse model. EPI-X4 exhibits antiviral activity against CXCR4-tropic HIV with IC₅₀ of 8.6 μM .

HY-P7061A

ALX 40-4C Trifluoroacetate 1 Publications Verification	Apelin Receptor (APJ) CXCR	Infection Endocrinology
ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P10333A

LIH383 TFA	CXCR	Neurological Disease Inflammation/Immunology
LIH383 TFA is an agonist of ACKR3 (CXCR7) (EC₅₀=0.61 nM). LIH383 TFA efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .

HY-P4911A

SDF-1α (human) TFA 2 Publications Verification	CXCR	Cardiovascular Disease
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to *CXCR4*. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .

HY-P11451

Pentixather	CXCR	Cancer
Pentixather is a radiolabeled peptide that can target *CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12* signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-P10427A

DV1 TFA	CXCR Dengue Virus	Infection
DV1 TFA is a *CXCR4* inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 TFA inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 TFA not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 TFA induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 TFA has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases .

HY-P4109

vMIP-II (1-21) NT21MP; V1 peptide	CXCR	Inflammation/Immunology Cancer
vMIP-II (1-21) (NT21MP) is an inhibitor of *CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4* by competing with 125I-SDF-1R for binding sites (IC₅₀=190 nM) .

HY-P4911

SDF-1α (human)	CXCR	Cardiovascular Disease
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to *CXCR4*. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .

HY-P5297

*DOTA-CXCR4-L*	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a *CXCR4* targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P1104

FC131	CXCR HIV	Infection
FC131 is a potent *CXCR4* antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

HY-P7061

ALX 40-4C	CXCR Apelin Receptor (APJ)	Infection Endocrinology
ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a K_i of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC₅₀ of 2.9 μM.

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-168095

CXCR4 antagonist 10	CXCR	Cancer
CXCR4 antagonist 10 (compound 21) is a potent antagonist of *CXCR4, with the IC₅₀* of 7.8 nM. CXCR4 antagonist 10 plays an important role in cancer research .

HY-144285

CXCR4 antagonist 4	CXCR HIV	Inflammation/Immunology
CXCR4 antagonist 4 is a potent, orally active *CXCR4* antagonist (IC₅₀=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC₅₀=7 nM) .

HY-P11011

Peptide R54 Pep R54; cxcr4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting *CXCR4* with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective *CXCR4* antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4810

Polyphemusin II-Derived Peptide T140	CXCR	Infection
Polyphemusin II-Derived Peptide (T140), a *CXCR4* inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .

HY-P1102A

TC14012 TFA	CXCR HIV	Infection Cancer
TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic *CXCR4* antagonist with an IC₅₀ of 19.3 nM. TC14012 TFA is a potent *CXCR7* agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity .

HY-P10973

Peptide R analogue 10	CXCR ERK	Cancer
Peptide R analogue 10 (compound 10) is an analog of the *CXCR4* antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a *CXCR4* inhibitor. TN14003 has antitumor activity .

HY-P4109A

vMIP-II (1-21) TFA NT21MP TFA; V1 peptide TFA	CXCR	Inflammation/Immunology Cancer
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of *CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4* by competing with 125I-SDF-1R for binding sites (IC₅₀=190 nM) .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .

HY-P4111A

Peptide R TFA	CXCR	Cancer
Peptide R (TFA) is a synthetic and specific *CXCR4* antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research .

HY-W019787

BAM-12P	Opioid Receptor CXCR	Neurological Disease
BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin. BAM-12P can activate human κ-opioid receptor (hKOR) with an EC₅₀ of 101 nM and a pEC₅₀ of 6.99. BAM-12P is a ligand for *CXCR7* with an EC₅₀ of 175 nM .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting *CXCR4* and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity *CXCR4* receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via *CXCR4* receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between *CXCR4* receptor and other chemical factor receptors .

HY-P10801

mC46 peptide C46 peptide	HIV	Infection
mC46 (C46) peptide is a membrane-associated fusion peptide inhibitor. mC46 peptide potently inhibits HIV-1 replication and entry. mC46 also inhibits CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, SIV, and SHIV .

HY-P11019

IS4	CXCR Calcium Channel	Cancer
IS4 is a selective *CXCR4* competitive antagonist, with an IC₅₀ of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca ²⁺ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases .

HY-W104862

4-Amino-D-phenylalanine 4-NH2-d-Phe	CXCR	Inflammation/Immunology
4-Amino-D-phenylalanine ([D-Phe(4-NH2)), a cyclic pentapeptide, inhibits CXCL12 binding to *CXCR4* in FC131, with an IC₅₀ of 0.1 μM .

HY-P10333

LIH383	CXCR	Neurological Disease Inflammation/Immunology
LIH383 is an agonist of ACKR3 (CXCR7) (EC₅₀=0.61 nM). LIH383 efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .

HY-P4095

NoxaBH3	CXCR	Cancer
NoxaBH3 is a cysteine-based cross-linked peptide with increased cell permeability and higher inhibitory activity against Mcl-1. NoxaBH3 binds to the endogenous *CXCR4* ligand to produce ubiquitin-Noxabh3 conjugate. NoxaBH3 is then delivered to cancer cells .

HY-P11011A

Peptide R54 acetate Pep R54 acetate; cxcr4 antagonist peptide 19 acetate	CXCR ERK Akt	Cancer
Peptide R54 acetate (Pep R54 acetate) is a *CXCR4* antagonist. Peptide R54 acetate inhibits CXCL12-dependent activation of pERK1/2 and pAKT. The combination of Peptide R54 acetate and Nivolumab (HY-P9903) suppresses melanoma growth. Peptide R54 (acetate) is applicable to research related to melanoma and ovarian cancer .

HY-P11728

Peptide E5	CXCR Apoptosis Caspase Akt ERK	Cancer
Peptide E5 is an antagonist targeting the CXCR4/CXCL12 axis. Peptide E5 blocks the *CXCR4/CXCL12* axis, downregulates *CXCR4* expression, and inhibits the phosphorylation of downstream Akt and Erk. Peptide E5 induces apoptosis, suppresses migration and adhesion of breast cancer cells. Peptide E5 inhibits CXCL12-mediated endothelial progenitor cell recruitment, thereby suppressing tumor angiogenesis. Peptide E5 is applicable to relevant research on breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990254

*Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)*	CXCR	Inflammation/Immunology Cancer
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse *CXCR3/CD183* IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 ⁺ and CD8 ⁺ T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .

HY-P99272

Ulocuplumab 1 Publications Verification BMS 936564; MDX 1338; Anti-Human cxcr4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of *CXCR5*, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-163480

PF-06835375	CXCR	Inflammation/Immunology
PF-06835375 is a selective, humanized *CXCR5*-targeting immunoglobulin G1 antibody. PF-06835375 depletes *CXCR5*-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases .

HY-P990394

*Anti-CXCR3/GPR9/CD183 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting *CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR*3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991227

*Anti-CD185/CXCR5 Antibody* BAY-924 antibody	CXCR	Cancer
Anti-CD185/CXCR5 Antibody is an antibody inhibitor, targeting to human CD185/CXCR5.

HY-P990395

*Anti-CXCR4/CD184 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets *CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR*4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991656

LY-2624587	CXCR Apoptosis p38 MAPK Akt	Cancer
LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting *CXCR4. LY-2624587 blocks SDF-1/CXCR4* interaction and SDF-1-induced GTP binding. LY-2624587 significantly inhibits cell migration and induces apoptosis in human lymphoma and leukemia cells. LY-2624587 also inhibits CXCR4 and SDF-1 mediated cell signaling including activation of MAPK and AKT. LY-2624587 can be used for human hematological malignancies like acute myeloid leukemia (AML) research .

HY-P991477

HFB-100204	CXCR	Inflammation/Immunology
HFB-100204 is a human monoclonal antibody (mAb) targeting *CXCR5. HFB-100204 reduces CXCR*5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .

HY-P991647

ALX-0651	CXCR	Cancer
ALX-0651 is a biparatopic humanized monoclonal antibody inhibitor targeting CXCR4. ALX-0651 inhibits hematopoietic stem cell trafficking, tumor progression and metastasis. ALX-0651 can be used for non-Hodgkin’s lymphoma and multiple myeloma research .

HY-P991568

AT009	CXCR	Cancer
AT009 is an anti-CXCR4 humanized monoclonal antibody. AT009 can be used for cancer research .

HY-P992036

*Anti-CXCR2 Antibody*	CXCR	Inflammation/Immunology
Anti-CXCR2 Antibody is an anti-CXCR2 antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991744

*Anti-Mouse CXCR4 Antibody (Cx4Mab-1)*	CXCR	Cancer
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .

HY-P992014

*Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5)*	CXCR	Inflammation/Immunology
Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting *CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3* .

HY-P992013

*Anti-CXCR3 Antibody (5H7)*	CXCR	Others
Anti-CXCR3 Antibody (5H7) is a mouse monoclonal antibody produced using *CXCR3* as the antigen. The recommended isotype control is human IgG1 kappa (HY-P99001).

HY-P991790

*Anti-Human/Monkey CXCR4 Antibody (12G5)*	CXCR	Inflammation/Immunology
Anti-Human/Monkey CXCR4 Antibody (12G5) reacts with human and monkey CXCR4. Anti-Human/Monkey CXCR4 Antibody (12G5) blocks the cognate ligand, CXCL12/SDF-1, and gp120/160 from binding to CXCR4. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .

HY-P991746

*Anti-Mouse CXCR2 Antibody (Cx2Mab-1)*	CXCR	Cancer
Anti-Mouse CXCR2 Antibody (Cx2Mab-1) reacts with mouse *CXCR2* targeting the N-terminal extracellular domain of CXCR2. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-P991781

*Anti-Mouse CXCR6 Antibody (Cx6Mab-1)*	CXCR	Inflammation/Immunology
Anti-Mouse CXCR6 Antibody (Cx6Mab-1) reacts with the N-terminal extracellular ligand-binding domain of mouse CXCR6. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979) .

HY-P992397

KY1051	CXCR	Cancer
KY1051 is a human monoclonal antibody targeting *CXCR4/CD184*. KY1051 can be used for research related to tumor immunology.

HY-P992405

MEDI-3185	CXCR	Cancer
MEDI-3185 is a potent *CXCR4* antagonist. MEDI-3185 binds *CXCR4* via CDR3H and ECL2 β-strand/β-strand interaction, blocks SDF-1 access and displaces SDF-1. MEDI-3185 can be used for the research of hematologic tumors, ovarian tumors .

HY-P992035

AMY109	Interleukin Related	Endocrinology
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with IC₅₀ values of 0.14 μg/mL and 0.37 μg/mL against human IL-8, a K_a of 36.8 pM for human IL-8, and a K_a of 380 pM for cynomolgus monkey IL-8.\nAMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of *CXCR1* and *CXCR2*, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis .

HY-P992439

PF-06747143	CXCR	Cancer
PF-06747143 is recombinant anti-human antibody targeting *CXCR4. PF-06747143 blocks CXCL12*-induced calcium flux, F-actin polymerization, chemotaxis, cell migration, and leukemic cell bone marrow homing. PF-06747143 reduces tumor burden and improves survival in mouse models of hematologic malignancies. PF-06747143 can be used for the research of chronic lymphocytic leukemia, acute myeloid leukemia, and hematologic malignancies .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100806

Kynurenic acid 5+ Cited Publications Quinurenic acid	Alkaloids Structural Classification Human Gut Microbiota Metabolites Neurological Disease Classification of Application Fields Quinoline Alkaloids Endogenous metabolite Disease Research Fields Endocrinology	iGluR Endogenous Metabolite Apoptosis CXCR GPR35
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of *GPR35/CXCR8*.

HY-N0011

Baohuoside I Maximum Cited Publications 18 Publications Verification Icariin-II; Icariside-II	Flavonols Classification of Application Fields Anti-aging Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Epimedium koreanum Nakai Phenols Polyphenols Berberidaceae Inflammation/Immunology Disease Research Fields Endocrinology Source Classification Cancer	CXCR Apoptosis
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of *CXCR4, downregulates CXCR*4 expression, induces apoptosis and shows anti-tumor activity.

HY-107512

Kynurenic acid sodium 5+ Cited Publications	Alkaloids Classification of Application Fields Quinoline Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	iGluR Apoptosis Endogenous Metabolite CXCR GPR35
Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of *GPR35/CXCR8*.

HY-101407

Nicotinamide N-oxide 3 Publications Verification	Alkaloids Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Oxidative Phosphorylation CXCR Drug Metabolite Endogenous Metabolite
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-100806R

Kynurenic acid (Standard) 5+ Cited Publications Quinurenic acid (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Quinoline Alkaloids Endogenous metabolite Source Classification	Reference Standards iGluR Endogenous Metabolite Apoptosis CXCR GPR35
Kynurenic acid (Standard) is the analytical standard of Kynurenic acid. This product is intended for research and analytical applications. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of *GPR35/CXCR8*.

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Structural Classification Alkaloids Classification of Application Fields Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-W062109

Olopatadine	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-N3255

Minecoside	Catalpa ovata G. Don Monophenols Phenols Plants Bignoniaceae Source Classification	CXCR STAT
Minecoside is a *CXCR4/STAT3* inhibitor with anticancer and anti-inflammatory activity. Minecoside decreases CXCR4 expression and suppresses STAT3 activation, thus to inhibit CXCL 12-induced invasion. Minecoside potently inhibits cancer metastasis and promotes apoptotic progression .

HY-N2573

Corydalmine L-Corydalmine; TLZ-16	Alkaloids Monophenols Corydalis yanhusuo W. T. Wang Phenols Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Fungal CXCR
Corydalmine (L-Corydalmine) inhibits spore germination of some plant pathogenic as well as saprophytic fungi . Corydalmine acts as an oral analgesic agent, exhibiting potent analgesic activity . Corydalmine alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway .

HY-N16578

Hypoglaucin A	Structural Classification Trillium erectum L. Plants Melanthiaceae Saccharides Monosaccharides Source Classification	CXCR
Hypoglaucin A is a *CXCR3* antagonist with an IC₅₀ of 0.47 μM. Hypoglaucin A can be used for the research of inflammation .

HY-101407R

Nicotinamide N-oxide (Standard)	Alkaloids Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Reference Standards CXCR Drug Metabolite Endogenous Metabolite
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the *CXCR2* receptor.

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Structural Classification Alkaloids Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Histamine Receptor CXCR
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-N0011R

Baohuoside I (Standard) Icariin-II (Standard); Icariside-II (Standard)	Flavonols Structural Classification Human Gut Microbiota Metabolites Flavonoids Epimedium koreanum Nakai Phenols Polyphenols Plants Endogenous metabolite Berberidaceae Source Classification	Reference Standards CXCR Apoptosis
Baohuoside I (Standard) is the analytical standard of Baohuoside I. This product is intended for research and analytical applications. Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.

HY-107512R

Kynurenic acid sodium (Standard)	Structural Classification Alkaloids Quinoline Alkaloids Endogenous metabolite Source Classification	iGluR Apoptosis Endogenous Metabolite CXCR GPR35 Reference Standards
Kynurenic acid (sodium) (Standard) is the analytical standard of Kynurenic acid (sodium). This product is intended for research and analytical applications. Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.

HY-N11723

Catenarin Katenarin	Quinones Microorganisms Anthraquinones Source Classification	CCR CXCR p38 MAPK JNK Calcium Channel
Catenarin, an anthraquinone compound, inhibits CCR5- and *CXCR4*-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

HY-N9858

Herpetin	Structural Classification Herpetospermum pedunculosum (Ser.) C. B. Clarke Cucurbitaceae Phenols Polyphenols Plants Source Classification	CXCR Wnt β-catenin
Herpetin is an active lignan. Herpetin acts as a bone marrow mesenchymal stem cell inducer that activates the *SDF-1/CXCR4* axis and the Wnt/β-catenin pathway. Herpetin is applicable to research related to acute liver injury .

Species:	Human (12) Mouse (1)
Tag:	SUMO (3) His (9) Tag Free (2) Myc (1) GST (1) Fc (1)
Source:	HEK293 (4) E. coli Cell-free (4) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P700537

	ACKR3 Protein, Human (His-SUMO) RDC1; cxcr7; RDC-1; CMKOR1; CXC-R7; cxcr-7; GPR159;	Human	E. coli
	ACKR3 is an atypical chemokine receptor that precisely controls chemokine levels and localization through high-affinity binding, operating independently of ligand-driven signaling. It acts as an interceptor, internalization receptor, and chemokine scavenger for CXCL11 and CXCL12/SDF1, inducing β-arrestin recruitment, ligand internalization, and MAPK pathway activation. ACKR3 Protein, Human (His-SUMO) is the recombinant human-derived ACKR3 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

HY-P790083

	CXCR2 Protein, Human (Cell-Free, His) CXC-R2; cxcr-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B (IL-8R B); IL-8 receptor type 2; cxcr2; IL8RB	Human	E. coli Cell-free
	CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (Cell-Free, His) is the recombinant human-derived CXCR2, expressed by E. coli Cell-free, with N-10His labeled tag. The total length of CXCR2 Protein, Human (Cell-Free, His) is 360 a.a.*.

HY-P72159

	CXCR4 Protein, Human (N-His-SUMO, C-Myc) C-X-C chemokine receptor type 4; CD184; CD184 antigen; Chemokine C X C motif; receptor 4; Chemokine CXC Motif Receptor 4; CXC-R4; cxcr-4; cxcr4; cxcr4_HUMAN; D2S201E; FB22; Fusin; HM89; HSY3RR; LAP 3; LAP3; LCR1; LESTR; NPY3R; NPYR; NPYRL; NPYY3; NPYY3R; SDF 1 receptor; SDF-1 receptor; WHIM; WHIMS	Human	E. coli
	The CXCR4 protein functions as a receptor for the CXC chemokine CXCL12/SDF-1, triggering an increase in intracellular calcium ions and activation of MAPK1/MAPK3. It is actively involved in AKT signaling, which is critical for regulating cell migration, especially in wound healing. CXCR4 Protein, Human (N-His-SUMO, C-Myc) is the recombinant human-derived CXCR4 protein, expressed by E. coli , with N-10*His, C-Myc, N-SUMO labeled tag.

HY-P702258

	CXCR4-VLP Protein, Human (HEK293, His) CXC-R4; cxcr-4; FB22; Fusin; HM89; LCR1; Leukocyte-derived seven transmembrane domain receptor; LESTR; Lipopolysaccharide-associated protein 3; LAP-3; LPS-associated protein 3; NPYRL; Stromal cell-derived factor 1 receptor; SDF-1 receptor; CD antigen CD184	Human	HEK293
	CXCR4-VLP Protein, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P72674

	CXCR4 Protein, Human (HEK293, Fc) C-X-C chemokine receptor type 4; CXC-R4; LESTR; LAP-3; NPYRL; CD184; SDF-1 receptor	Human	HEK293
	The CXCR4 protein functions as a receptor for the CXC chemokine CXCL12/SDF-1, triggering an increase in intracellular calcium ions and activation of MAPK1/MAPK3. It is actively involved in AKT signaling, which is critical for regulating cell migration, especially in wound healing. CXCR4 Protein, Human (HEK293, Fc) is the recombinant human-derived CXCR4 protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P700546

	CXCR4 Protein, Human (Cell-Free, His) C-X-C chemokine receptor type 4; CXC-R4; LESTR; LAP-3; NPYRL; CD184; SDF-1 receptor	Human	E. coli Cell-free
	The CXCR4 protein functions as a receptor for the CXC chemokine CXCL12/SDF-1, triggering an increase in intracellular calcium ions and activation of MAPK1/MAPK3. It is actively involved in AKT signaling, which is critical for regulating cell migration, especially in wound healing. CXCR4 Protein, Human (Cell-Free, His) is the recombinant human-derived CXCR4 protein, expressed by E. coli Cell-free , with N-6*His labeled tag.

HY-P72160

	CXCR4 Protein, Human (GST) C-X-C chemokine receptor type 4; CD184; CD184 antigen; Chemokine C X C motif; receptor 4; Chemokine CXC Motif Receptor 4; CXC-R4; cxcr-4; cxcr4; cxcr4_HUMAN; D2S201E; FB22; Fusin; HM89; HSY3RR; LAP 3; LAP3; LCR1; LESTR; Leukocyte derived seven transmembrane domain receptor; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide associated protein 3; Neuropeptide Y receptor Y3; NPY3R; NPYR; NPYRL; NPYY3; NPYY3R; Probable G protein coupled receptor lcr1 homolog; SDF 1 receptor; SDF-1 receptor; SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR; Stromal cell derived factor 1 receptor; Stromal cell-derived factor 1 receptor; WHIM; WHIMS	Human	E. coli
	The CXCR4 protein functions as a receptor for the CXC chemokine CXCL12/SDF-1, triggering an increase in intracellular calcium ions and activation of MAPK1/MAPK3. It is actively involved in AKT signaling, which is critical for regulating cell migration, especially in wound healing. CXCR4 Protein, Human (GST) is the recombinant human-derived CXCR4 protein, expressed by E. coli , with N-GST labeled tag.

HY-P702257

	CXCR2 Protein, Mouse (Cell-Free, His) C-X-C chemokine receptor type 2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; CD182	Mouse	E. coli Cell-free
	CXCR2 protein acts as a receptor for interleukin-8 and induces neutrophil activation through the G protein-mediated phosphatidylinositol-calcium second messenger system. In addition to IL-8, CXCR2 also exhibits high-affinity binding to ligands such as CXCL3, GRO/MGSA, and NAP-2. CXCR2 Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived CXCR2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

HY-P700536

	CXCR2 Protein, Human (His-SUMO) C-X-C motif chemokine receptor 2; IL8RB, interleukin 8 receptor, beta; C-X-C chemokine receptor type 2; CD182; CMKAR2;	Human	E. coli
	CXCR2, the receptor for interleukin-8 (IL-8), orchestrates neutrophil activation through a G-protein-mediated phosphatidylinositol-calcium second messenger system upon IL-8 binding. Exhibiting high-affinity binding to IL-8, CXCR2 also interacts with other ligands like CXCL3, GRO/MGSA, and NAP-2. The involvement of GNAI2 underscores the intricate signaling mechanisms regulating neutrophil function through CXCR2. CXCR2 Protein, Human (His-SUMO) is the recombinant human-derived CXCR2 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

HY-P700539A

	CXCR3 Protein, Human (His) G protein coupled receptor 9 , GPR9; C-X-C chemokine receptor type 3; CD183; CKR L2; CMKAR3; IP10 R; MigR; CXC-R3; cxcr-3; Mig receptor; IP10 receptor; IP-10 receptor; G protein-coupled receptor 9; chemokine C-X-C receptor 3; interferon-inducible protein 10 receptor; GPR9; CD182; Mig-R; CKR-L2; IP10-R;	Human	E. coli
	CXCR3 Protein, Human (His) is the recombinant human-derived CXCR3, expressed by E. coli , with C-His tag.

HY-P700539

	CXCR3 Protein, Human (Cell-Free, His) G protein coupled receptor 9 , GPR9; C-X-C chemokine receptor type 3; CD183; CKR L2; CMKAR3; IP10 R; MigR; CXC-R3; cxcr-3; Mig receptor; IP10 receptor; IP-10 receptor; G protein-coupled receptor 9; chemokine C-X-C receptor 3; interferon-inducible protein 10 receptor; GPR9; CD182; Mig-R; CKR-L2; IP10-R;	Human	E. coli Cell-free
	The CXCR3 protein acts as a receptor for CXC chemokines (CXCL9, CXCL10, and CXCL11), affecting human mesangial cells (HMC) through G protein signaling. It binds CCL21 and may promote cell chemotaxis. CXCR3 Protein, Human (Cell-Free, His) is the recombinant human-derived CXCR3 protein, expressed by E. coli Cell-free , with C-10*His labeled tag.

HY-P704558

	CXCR3 Protein-VLP, Human (HEK293) G protein coupled receptor 9 , GPR9; C-X-C chemokine receptor type 3; CD183; CKR L2; CMKAR3; IP10 R; MigR; CXC-R3; cxcr-3; Mig receptor; IP10 receptor; IP-10 receptor; G protein-coupled receptor 9; chemokine C-X-C receptor 3; interferon-inducible protein 10 receptor; GPR9; CD182; Mig-R; CKR-L2; IP10-R;	Human	HEK293
	CXCR3 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

HY-P704224

	CXCR5/CD185 Protein-VLP, Human (HEK293) BLR1; L CD185; L MDR15; LC-X-C chemokine receptor type 5; LBurkitt lymphoma receptor 1; LMonocyte-derived receptor 15 (MDR-15)	Human	HEK293
	CXCR5/CD185 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-100806S

Kynurenic acid-d5 1 Publications Verification
Kynurenic acid-d₅ is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8 .

HY-10046S

Plerixafor-d4
Plerixafor-d₄ is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC₅₀ of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC₅₀ of 1-10 nM .

HY-W062109S

Olopatadine-d6

Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AS

Olopatadine-d3 hydrochloride

Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-W701397

Nicotinamide N-oxide-d4
Nicotinamide N-oxide-d₄ is the deuterium labeled Nicotinamide N-oxide (HY-101407). Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.

HY-B0426AS2

Olopatadine-d6 hydrochloride

Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

Host:	Mouse (8) Rabbit (7)
Reactivity:	Human (15) Rat (5) Mouse (5)
Application:	IHC-P (7) ICC/IF (6) IP (1) IHC-F (1) WB (11) FC (10) ELISA (10)
Isotype:	IgG (7) IgG1 (7)
Conjugation:	Non-conjugated (18)
Clonality:	Polyclonal (3) Monoclonal (6) Monoclonal Antibody (4) Recombinant (3)
Modification:	Unmodified (13)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83212

	*GPCR RDC1/CXCR-7 Antibody (YA2957)* RDC1; cxcr7; RDC-1; CMKOR1; CXC-R7; cxcr-7; GPR159	WB	Human, Mouse, Rat
	GPCR RDC1/CXCR-7 Antibody (YA2957) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GPCR RDC1/CXCR-7.

HY-P84210

	*GPCR RDC1/CXCR-7 Antibody (YA3907)* RDC1; cxcr7; RDC-1; CMKOR1; CXC-R7; cxcr-7; GPR159	IHC-P, ICC/IF, FC, ELISA	Human
	GPCR RDC1/CXCR-7 Antibody (YA3907) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GPCR RDC1/CXCR-7.

HY-P83212A

	*GPCR RDC1/CXCR-7 Antibody (YA2957)(PBS only)* RDC1; cxcr7; RDC-1; CMKOR1; CXC-R7; cxcr-7; GPR159	WB	Human, Mouse, Rat
	GPCR RDC1/CXCR-7 Antibody (YA2957) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GPCR RDC1/CXCR-7.

HY-P84210A

	*GPCR RDC1/CXCR-7 Antibody (YA3907)(PBS only)* RDC1; cxcr7; RDC-1; CMKOR1; CXC-R7; cxcr-7; GPR159	IHC-P, ICC/IF, FC, ELISA	Human
	GPCR RDC1/CXCR-7 Antibody (YA3907) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GPCR RDC1/CXCR-7.

HY-P84355

	CXCR3 Antibody (YA4052) cxcr3; GPR9; MigR; CD182; Mig-R; CKR-L2; CMKAR3; IP10-R	WB, IHC-P, FC, ELISA	Human
	CXCR3 Antibody (YA4052) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR3.

HY-P84207A

	CXCR2 Antibody (YA3904)(PBS only) cxcr2; IL8R2; IL8RA; IL8RB; CMKAR2; CDw128b	IHC-P, ICC/IF, FC, ELISA	Human
	CXCR2 Antibody (YA3904) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR2.

HY-P84355A

	CXCR3 Antibody (YA4052)(PBS only) cxcr3; GPR9; MigR; CD182; Mig-R; CKR-L2; CMKAR3; IP10-R	WB, IHC-P, FC, ELISA	Human
	CXCR3 Antibody (YA4052) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CXCR3.

HY-P81158

	CXCR2 Antibody CXC-chemokine receptor 2; CD 182; CD182; CD182 antigen; CDw128b; Chemokine (CXC) receptor 2; CMKAR2; cxcr 2; CXC R2; CXC-R2; cxcr2_HUMAN; C-X-C chemokine receptor type 2; cxcr-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; IL-8 receptor type 2.	WB, IHC-P, ELISA	Human
	CXCR2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CXCR2.

HY-P82361

	CXCR5 Antibody (YA2106) cxcr5; BLR1; MDR15; C-X-C chemokine receptor type 5; CXC-R5; cxcr-5; Burkitt lymphoma receptor 1; Monocyte-derived receptor 15; MDR-15; CD185	WB, ICC/IF, FC	Human, Mouse, Rat
	CXCR5 Antibody (YA2106) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCR5.

HY-P81089

	CXCR4 Antibody C-X-C chemokine receptor type 4; CXC-R4; cxcr-4; Stromal cell-derived factor 1 receptor; SDF-1 receptor; Fusin; Leukocyte-derived seven transmembrane domain receptor; LESTR; CD184 antigen; cxcr4_HUMAN.	WB, IHC-P, IHC-F, ICC/IF, FC, ELISA	Human, Mouse, Rat
	CXCR4 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CXCR4.

HY-P83796

	CD186 Antibody (YA3493) cxcr6; BONZO; CDw186; STRL33; TYMSTR	WB, FC, ELISA	Human
	CD186 Antibody (YA3493) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD186.

HY-P83796A

	CD186 Antibody (YA3493)(PBS only) cxcr6; BONZO; CDw186; STRL33; TYMSTR	WB, FC, ELISA	Human
	CD186 Antibody (YA3493) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD186.

HY-P84973

	CXCR5 Antibody (YA7081) BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt lymphoma receptor 1 antibody; Burkitt lymphoma receptor 1 GTP binding protein antibody; Burkitt lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; cxcr 5 antibody; cxcr-5 antibody; cxcr5 antibody; cxcr5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody;
	CXCR5 Antibody is a non-conjugated antibody, targeting to CD185.

HY-P85022

	CXCR5 Antibody (YA4714) BLR1; MDR15; BLR 1 antibody; BLR1 antibody; Burkitt lymphoma receptor 1 antibody; Burkitt lymphoma receptor 1 GTP binding protein antibody; Burkitt lymphoma receptor 1; GTP binding protein; chemokine; C-X-C motif; receptor 5; antibody; C X C chemokine receptor type 5 antibody; C-X-C chemokine receptor type 5 antibody; CD 185 antibody; CD185 antibody; CD185 antigen antibody; Chemokine; C-X-C motif; receptor 5 antibody; Chemokine C X C motif receptor 5 antibody; Chemokine CXC motif receptor 5 antibody; Chemokine receptor 5 antibody; CXC chemokine receptor type 5 antibody; CXC R5 antibody; CXC-R5 antibody; cxcr 5 antibody; cxcr-5 antibody; cxcr5 antibody; cxcr5_HUMAN antibody; MDR 15 antibody; MDR-15 antibody; MDR15 antibody; MGC117347 antibody; Monocyte derived receptor 15 antibody; Monocyte-derived receptor 15 antibody;	FC, ELISA	Human
	CXCR5 Antibody (YA4714) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CXCR5.

HY-P81188

	CXCR3 Antibody cxcr3_HUMAN; Interferon-inducible protein 10 receptor; IP-10 receptor; C-X-C chemokine receptor type 3; CD 183; CD183; CD183 antigen; G protein-coupled receptor 9; G Protein Coupled Receptor 9; Chemokine (C X C motif) receptor 3; Chemokine (C X C) receptor 3; C-X-C Chemokine receptor; CXC Motif Receptor 3; Chemokine CXC Motif Receptor 3; CKRL2; CKR L2; CKR-L2; GPR9; CXC-R3; cxcr-3; IP10 receptor.	WB	Human, Mouse, Rat
	CXCR3 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CXCR3.

HY-P83692

	CXCR3 Antibody (YA3426) cxcr3_HUMAN; Interferon-inducible protein 10 receptor; IP-10 receptor; C-X-C chemokine receptor type 3; CD 183; CD183; CD183 antigen; G protein-coupled receptor 9; G Protein Coupled Receptor 9; Chemokine (C X C motif) receptor 3; Chemokine (C X C) receptor 3; C-X-C Chemokine receptor; CXC Motif Receptor 3; Chemokine CXC Motif Receptor 3; CKRL2; CKR L2; CKR-L2; GPR9; CXC-R3; cxcr-3; IP10 receptor.	WB, ICC/IF, IP	Human
	CXCR3 Antibody (YA3426) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCR3.

HY-P84971

	CD183 Antibody (YA4663) cxcr3; G protein-coupled receptor 9; GPR9; CKR-L2; IP10 receptor; IP10-R; Mig receptor; Mig-R; C-X-C chemokine receptor type 3 antibody; CD 183 antibody; CD182 antibody; CD183 antibody; Chemokine; C X C motif; receptor 3 antibody; Chemokine; C X C; receptor 3 antibody; Chemokine CXC Motif Receptor 3 antibody; CKR L2 antibody; CKR-L2 antibody; CKRL2 antibody; CMKAR3 antibody; CXC-R3 antibody; cxcr-3 antibody; cxcr3 antibody; cxcr3_HUMAN antibody; G Protein Coupled Receptor 9 antibody; G protein-coupled receptor 9 antibody; GPR9 antibody; Interferon-inducible protein 10 receptor antibody; IP-10 receptor antibody; IP10 antibody; IP10 R antibody; IP10 receptor antibody; IP10-R antibody; IP10R antibody; Mig R antibody; Mig receptor antibody; Mig-R antibody; MIGR antibody;
	CD183 Antibody (YA4663) is a non-conjugated antibody, targeting to CD183.

HY-P84972

	CD184 Antibody (YA4664) cxcr4; FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; LAP-3; LESTR; NPY3R; NPYRL; WHIMS; HSY3RR; NPYY3R; WHIMS1; D2S201E; C-X-C chemokine receptor type 4 antibody; CD184 antibody; CD184 antigen antibody; Chemokine; C X C motif; receptor 4 antibody; Chemokine CXC Motif Receptor 4 antibody; CXC-R4 antibody; cxcr-4 antibody; cxcr4 antibody; cxcr4_HUMAN antibody; D2S201E antibody; FB22 antibody; Fusin antibody; HM89 antibody; HSY3RR antibody; LAP 3 antibody; LAP3 antibody; LCR1 antibody; LESTR antibody; Leukocyte derived seven transmembrane domain receptor antibody; Leukocyte-derived seven transmembrane domain receptor antibody; Lipopolysaccharide associated protein 3 antibody; Neuropeptide Y receptor Y3 antibody; NPY3R antibody; NPYR antibody; NPYRL antibody; NPYY3 antibody; NPYY3R antibody; Probable G protein coupled receptor lcr1 homolog antibody; SDF 1 receptor antibody; SDF-1 receptor antibody; SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR antibody; Stromal cell derived factor 1 receptor antibody; Stromal cell-derived factor 1 receptor antibody; WHIM antibody; WHIMS antibody;
	CD184 Antibody (YA4664) is a non-conjugated antibody, targeting to CD184.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS03403

CXCR3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174728

*Human CXCR1 mRNA*		mRNA Chemokine & Receptors
Human CXCR1 mRNA encodes the human C-X-C motif chemokine receptor 1 (CXCR1) protein, a member of the G-protein-coupled receptor family. CXCR1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system.

HY-RS03400

CXCR2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03406

CXCR4 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174724

*Human CXCR5 mRNA*		mRNA Chemokine & Receptors
Human CXCR5 mRNA encodes the human C-X-C motif chemokine receptor 5 (CXCR5) protein, a multi-pass membrane protein that belongs to the CXC chemokine receptor family. CXCR5 is involved in B-cell migration into B-cell follicles of spleen and Peyer patches.

HY-174726

*Human CXCR3 mRNA*		mRNA Chemokine & Receptors
Human CXCR3 mRNA encodes the human C-X-C motif chemokine receptor 3 (CXCR3) protein, G protein-coupled receptor. Chemokines bind to CXCR3 protein can induce cellular responses that are involved in leukocyte traffic, integrin activation, cytoskeletal changes and chemotactic migration.

HY-174727

*Human CXCR2 mRNA*		mRNA Chemokine & Receptors
Human CXCR2 mRNA encodes the human C-X-C motif chemokine receptor 2 (CXCR2) protein, a member of the G-protein-coupled receptor family. CXCR2 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth.

HY-RS03401

Cxcr2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03408

Cxcr4 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03407

Cxcr4 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03399

Cxcr1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03398

Cxcr1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03397

CXCR1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03404

Cxcr3 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03409

CXCR5 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR5 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03410

CXCR6 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CXCR6 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03402

Cxcr2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16995

Cxcr5 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS23438

Cxcr5 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03405

Cxcr3 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03412

Cxcr6 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Cxcr6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03411

Cxcr6 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Cxcr6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174725

*Human CXCR4 mRNA*		mRNA Chemokine & Receptors
Human CXCR4 mRNA encodes the human C-X-C motif chemokine receptor 4 (CXCR4) protein, a CXC chemokine receptor specific for stromal cell-derived factor-1. CXCR4 acts with the CD4 protein to support HIV entry into cells.

HY-174723

*Human CXCR6 mRNA*		mRNA Chemokine & Receptors
Human CXCR6 mRNA encodes the human C-X-C motif chemokine receptor 6 (CXCR6) protein, a G protein-coupled receptor that belongs to the CXC chemokine receptor family. CXCR6 and its exclusive ligand, chemokine ligand 16 (CCL16), are part of a signalling pathway that regulates T lymphocyte migration to various peripheral tissues (the liver, spleen red pulp, intestine, lungs, and skin) and promotes cell-cell interaction with dendritic cells and fibroblastic reticular cells.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks